At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 76 enrolled
Drug / intervention
Collagenase clostridium histolyticum +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2a, Double-blind, Randomized, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety and Effectiveness of AA4500 in the Treatment of Dupuytren's Disease Nodules
In Brief
A Phase 2 clinical trial evaluating Collagenase clostridium histolyticum and Placebo for Dupuytren's Disease. Completed, enrolled 76 participants across 11 sites in 2 countries.
Detailed Summary
The objectives of this study are to assess the safety and effectiveness of AA4500 in treating palmar Dupuytren's disease nodules.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDupuytren's Disease
CountriesAustralia, United States
Collaborators--
Timeline
Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
Enrollment StartJul 2014
First PostedJul 2014
Primary CompletionDec 2014
TodayJul 2026
First PostedJul 18, 2014
Enrollment StartJul 1, 2014
Primary CompletionDec 1, 2014
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 12.0 years ago
Interventions
Collagenase clostridium histolyticumbiological
Single injection into nodule
Placebobiological
Single injection into nodule